

RESEARCH LETTER

Open Access

# Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times?



Miranda van Berkel<sup>1</sup>, Matthijs Kox<sup>2,3</sup>, Tim Frenzel<sup>2,3</sup>, Peter Pickkers<sup>2,3</sup>, Jeroen Schouten<sup>2,3\*</sup> , on behalf of the RCI-COVID-19 study group

**Keywords:** COVID-19, Procalcitonin, Antimicrobial stewardship

On initial presentation, differentiation between early-stage coronavirus disease 2019 (COVID-19) and classical bacterial community-acquired pneumonia can be challenging. Furthermore, COVID-19 patients may develop a hyperinflammatory phase later in their disease process, which is particularly difficult to distinguish from a secondary bacterial infection. As a consequence, 72% of COVID-19 patients receive empirical antibiotic therapy during hospital stay [1]. Antibiotic overuse undoubtedly leads to an exacerbation of another—slowly progressive—pandemic: antimicrobial resistance [2].

Procalcitonin (PCT) has proven useful in the early diagnosis of lower respiratory tract infections of bacterial origin [3]. Furthermore, in the ICU setting, serial measurement of PCT can safely guide the withdrawal of antibiotic therapy [4].

In patients with COVID-19, C-reactive protein (CRP) is usually increased on presentation while PCT is often

low [5]. PCT appears to increase in COVID patients with severe disease and/or in those presenting with secondary bacterial infections [6]. Longitudinal data on both biomarkers in COVID-19 infections are currently lacking. Also, it is unclear to what extent PCT and CRP predict the occurrence of secondary infections in these patients.

Data from 66 COVID-19 ICU patients were recorded in the Good Clinical Practice (GCP)-compliant data management system Castor (Castor EDC, Amsterdam, The Netherlands). PCT was determined using the Elecsys BRAHMS procalcitonin assay (Thermo Fisher Scientific), whereas CRP was determined using an immunoturbidimetric assay, both on a Cobas 8000 immunoanalyzer (Roche Diagnostics). Secondary infection was defined as “any infectious episode” evidenced by the presence of positive cultures and time-stamped at the day the culture was performed. Infectious episodes were independ-

\* Correspondence: [jeroen.schouten@radboudumc.nl](mailto:jeroen.schouten@radboudumc.nl)

<sup>2</sup>Department of Intensive Care Medicine, Radboud University Medical Centre, Postbus 9101, 6500 HB Nijmegen, The Netherlands

<sup>3</sup>Radboud Center for Infectious Diseases, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Table 1** Patient characteristics

	Secondary infection (n = 33)	No secondary infection (n = 33)	p value
<b>Sex</b>			
Male, n (%)	26 (79%)	23 (70%)	0.57
Female, n (%)	7 (21%)	10 (30%)	
Age, years	67 [60–73]	65 [56–70]	0.17
BMI, kg/m <sup>2</sup>	27.6 [25.4–31.1]	27.7 [24.3–30.7]	0.40
APACHE II	15 [13–19]	15 [10–19]	0.77
Days between COVID-19 symptoms and hospital admission	7 [4–10]	7 [5–11]	0.72
Days between COVID-19 symptoms and ICU admission	10 [7–13]	10 [6–14]	0.96
Day of secondary infection (relative to hospital admission)	16 [13–22]	NA	
Day of secondary infection (relative to ICU admission)	14 [9–21]	NA	
<b>Medical history, n (%)</b>			
Cardiovascular insufficiency	9 (27%)	9 (27%)	1.00
Hypertension	17 (52%)	16 (48%)	1.00
Respiratory insufficiency	2 (6%)	3 (9%)	1.00
Renal insufficiency	0 (0%)	1 (3%)	1.00
Metastatic neoplasm	2 (6%)	3 (9%)	1.00
Immunological insufficiency	0 (0%)	1 (3%)	1.00
COPD	3 (9%)	3 (9%)	1.00
Diabetes	11 (33%)	4 (12%)	0.08
Hematologic malignancy	0 (0%)	1 (3%)	1.00

Continuous data are presented as median [interquartile range]. p values were calculated using Mann-Whitney U tests (continuous data) and Fisher exact tests (categorical data)  
NA not applicable

ently determined by two ICU physicians (JS and HT). In case of incongruency, a third ICU physician (PP) was consulted. In case of multiple secondary infections, only the first infectious episode was analyzed.

Half of the patients ( $n = 33$ ) developed a secondary infection during ICU admission. No significant differences in characteristics were observed between patients who did or did not develop a secondary infection (Table 1). In patients without secondary infection, both PCT and CRP decreased over time (Fig. 1a), with PCT values lower (peak geometric mean [95% CI] of 0.64 [0.32–1.27]  $\mu\text{g/L}$ ) than CRP (peak geometric mean [95% CI] of 192 [107–342] mg/L) compared to their respective cutoff values for bacterial infection (< 0.5  $\mu\text{g/L}$  and < 100 mg/L, respectively). A significant increase in both PCT and CRP levels was observed in case of the occurrence of a secondary infection (Fig. 1b). The receiver operating curve analysis of PCT and CRP yielded AUCs of 0.80 and 0.76, respectively (Fig. 1c). In patients with PCT < 0.25  $\mu\text{g/L}$ , the negative predictive value was 81%, whereas PCT levels of > 1.00  $\mu\text{g/L}$  had a

positive predictive value of 93%. Intermediate PCT levels were of limited diagnostic value. For CRP, predictive values were less robust (Fig. 1c).

The use of biomarkers to predict secondary infections in ICU patients warrants reappraisal in times of COVID-19. We demonstrate that COVID-19 patients who do not develop a bacterial infection present with high initial CRP levels and low-moderate PCT levels that gradually decrease over time. Furthermore, our data show that, during ICU admission, PCT levels of > 1.00  $\mu\text{g/L}$  rule in, whereas concentrations of < 0.25  $\mu\text{g/L}$  rule out secondary bacterial infections with good predictive values.

With regard to ICU antimicrobial stewardship, initiation of empirical antibacterial therapy in ICU patients with low PCT levels should probably not be started. As CRP is consistently elevated, this biomarker does not have predictive value for bacterial infections in the initial phase of COVID-19. Later on during ICU stay, serial PCT and, to a lesser extent, CRP may help to identify or rule out nosocomial bacterial infections and prompt appropriate use of antibiotic therapy.




Fig. 1 (See legend on next page.)

(See figure on previous page.)

**Fig. 1** Kinetics and predictive value of procalcitonin and C-reactive protein in COVID-19 patients. **a** Serial values of procalcitonin (PCT, left panel) and C-reactive protein (CRP, right panel) in patients with COVID-19 who did not develop a secondary infection ( $n = 33$ ). Data are aligned on the day of the start of COVID symptoms, which is designated day 0. The arrows indicate the median day of hospital admission (day 7, interquartile range [5–11]) and the median day of ICU admission (day 10, interquartile range [6–14]). Data are expressed as geometric means with 95% confidence interval. When biomarker variables were not measured daily, data were binned into bins spanning 2 days using a custom script made in R-studio v3.6.2 ([www.r-project.org](http://www.r-project.org)). If more than one value was present in these 2-day bins, the mean value was used. **b** Serial values of PCT (left panel) and CRP (right panel) in patients ( $n = 33$ ) with COVID-19 who did develop ( $n = 33$ ) or did not ( $n = 33$ ) develop a secondary infection. Data are aligned on the day of secondary infection, which is designated day 0. For the “no secondary infection” group, data are aligned on the median day of infection in the “secondary infection” group (day 14 after ICU admission). Data are expressed as geometric means with 95% confidence interval. Data were binned into bins spanning 2 days (see **a** for details). The groups were compared using mixed-models analysis (time  $\times$  group interaction factor) on log-transformed data.  $p$  values placed under graph titles reflect between-group differences over the entire time period (day  $-10$  until day 14).  $p$  values for day  $-10$  until day 0 and day 0 until day 14 are shown on the top left and right. **c** Receiver operating curve to illustrate sensitivity and specificity of PCT (left panel) and CRP (right panel) levels to predict secondary infection. Binned PCT/CRP data of day  $-1$  and day 0 were used (see **a** for details). Positive predictive value (PPV), negative predictive value (NPV), and incidence are provided for the depicted concentrations

### Abbreviations

COVID-19: Coronavirus disease 2019; PCT: Procalcitonin; CRP: C-reactive protein

### Acknowledgements

Next to the authors of this letter, the RCI-COVID-19 study group consists of Denise Waanders, Niklas Bruse, Emma Kooistra, Hugo Touw, Pleun Hemelaar, Remi Beunders, Johannes van der Hoeven, Sjef van der Velde, Hetty van der Eng, Noortje Rovers, Margreet Klop-Riehl, Jelle Gerretsen, Nicole Waalders, Wout Claassen, Hidde Heesakkers, Tirsa van Schaik, Mihai Netea, Leo Joosten, Nico Janssen, Inge Grondman, Aline de Nooijer, Quirijn de Mast, Martin Jaeger, Ilse Kouijzer, Helga Dijkstra, Heidi Lemmers, Reinout van Crevel, Josephine van de Maat, Gerine Nijman, Simone Moorlag, Esther Taks, Priya Debisarun, Heiman Wertheim, Joost Hopman, Janette Rahamat-Langendoen, Chantal Bleeker-Rovers, Esther Fasse, Esther van Rijssen, Manon Kolkman, Bram van Cranenbroek, Ruben Smeets, and Irma Joosten. All of these authors are affiliated to the Radboud Center of Infectious Diseases. The names of the individual members of the group should be searchable through their individual PubMed records.

The authors would like to thank Hugo Touw (HT) for scoring secondary infection episodes.

### Authors' contributions

MvB, MK, PP, TF, and JS designed the study. PP and JS scored the secondary infection episodes. TF, MK, EK, and PP designed the database/collected the patient-related information. MvB, DW, MK, and PP analyzed and interpreted the data. MvB and JS drafted the manuscript. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors revised and approved the final manuscript for publication.

### Funding

Not applicable

### Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

### Ethics approval and consent to participate

This study was performed in accordance with the ethical standards of the institutional and/or national research committee.

### Consent for publication

The authors declare that they all consent to publication.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup>Department of Laboratory Medicine, Radboud University Medical Centre, 6500 HB Nijmegen, The Netherlands. <sup>2</sup>Department of Intensive Care Medicine, Radboud University Medical Centre, Postbus 9101, 6500 HB Nijmegen, The Netherlands. <sup>3</sup>Radboud Center for Infectious Diseases, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands.

Received: 14 August 2020 Accepted: 14 September 2020

Published online: 06 October 2020

### References

1. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, Satta G, Cooke G, Holmes A. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. *Clin Infect Dis:ciaa530* <https://doi.org/10.1093/cid/ciaa530>.
2. Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don't neglect antimicrobial stewardship principles! *Clin Microbiol Infect.* 2020; 26(7):808–10. <https://doi.org/10.1016/j.cmi.2020.04.024>.
3. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. *BMC Med.* 2011;9(1): 107 <https://doi.org/10.1186/1741-7015-9-107>.
4. de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. *Lancet Infect Dis.* 2016;16(7):819–27. [https://doi.org/10.1016/S1473-3099\(16\)00053-0](https://doi.org/10.1016/S1473-3099(16)00053-0).
5. Lippi, Giuseppe, et Mario Plebani. 2020. « Laboratory abnormalities in patients with COVID-2019 infection ». *Clinical Chemistry and Laboratory Medicine (CCLM)*, n° 0. <https://www.degruyter.com/view/journals/cclm/ahead-of-print/article-10.1515-cclm-2020-0198/article-10.1515-cclm-2020-0198.xml>.
6. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA.* 2020;323(11):1061–9 <https://doi.org/10.1001/jama.2020.1585>.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

